338 related articles for article (PubMed ID: 34096329)
21. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis.
Kearney CM; Sangani R; Shankar D; O'Connor GT; Law AC; Walkey AJ; Bosch NA
Ann Am Thorac Soc; 2024 Jun; 21(6):866-874. PubMed ID: 38241013
[No Abstract] [Full Text] [Related]
22. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
[TBL] [Abstract][Full Text] [Related]
23. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
[No Abstract] [Full Text] [Related]
24. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
25. HFA-BDP Metered-Dose Inhaler Exhaled Through the Nose Improves Eosinophilic Chronic Rhinosinusitis With Bronchial Asthma: A Blinded, Placebo-Controlled Study.
Kobayashi Y; Yasuba H; Asako M; Yamamoto T; Takano H; Tomoda K; Kanda A; Iwai H
Front Immunol; 2018; 9():2192. PubMed ID: 30337921
[No Abstract] [Full Text] [Related]
26. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
[TBL] [Abstract][Full Text] [Related]
27. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps.
Matsuno O; Minamoto S
Pulm Pharmacol Ther; 2020 Oct; 64():101965. PubMed ID: 33039667
[TBL] [Abstract][Full Text] [Related]
28. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
Sridhar S; Liu H; Pham TH; Damera G; Newbold P
Respir Res; 2019 Jan; 20(1):14. PubMed ID: 30658649
[TBL] [Abstract][Full Text] [Related]
29. Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment.
Mansur AH
Respir Med Case Rep; 2022; 35():101559. PubMed ID: 34976716
[TBL] [Abstract][Full Text] [Related]
30. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
32. Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis.
Tsurumaki H; Matsuyama T; Ezawa K; Koga Y; Yatomi M; Aoki-Saito H; Chikamatsu K; Hisada T
Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31277327
[TBL] [Abstract][Full Text] [Related]
33. Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.
Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
Intern Med; 2022; 61(11):1663-1671. PubMed ID: 35650114
[TBL] [Abstract][Full Text] [Related]
34. [The Effectiveness of Mepolizumab and Benralizumab in a Real-Life Cohort of Patients with Severe Eosinophilic Asthma].
Espinosa de Los Monteros Garde MJ; Romero Sanz V; Blázquez Romero C
Open Respir Arch; 2021; 3(2):100103. PubMed ID: 37497072
[TBL] [Abstract][Full Text] [Related]
35. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
36. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
37. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
[TBL] [Abstract][Full Text] [Related]
38. Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2.
Carstens D; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Chung Y
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2150-2161.e4. PubMed ID: 37146880
[TBL] [Abstract][Full Text] [Related]
39. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
[TBL] [Abstract][Full Text] [Related]
40. Exploring the risk of infection events in patients with asthma receiving
Giossi R; Pani A; Schroeder J; Scaglione F
Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]